-

04:09:27 AM

MRSN Stock News

MRSN - Mersana Therapeutics Inc

02/01/23 8:00 AM

Nasdaq : MRSN

clinical trial

Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline

RHEA-AI

neutral

01/25/23 8:00 AM

Nasdaq : MRSN

clinical trial

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting

RHEA-AI

very positive

01/06/23 4:05 PM

Nasdaq : MRSN

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

RHEA-AI

very positive

01/06/23 7:00 AM

Nasdaq : MRSN

Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones

Report top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential U.S. commercial launch in 2024 Advance Phase 3 UP-NEXT and Phase 1 UPGRADE-A trials in platinum-sensitive ovarian cancer Advance XMT-1660 and XMT-2056 Phase 1

RHEA-AI

very positive

12/22/22 4:05 PM

Nasdaq : MRSN

Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary immunostimulatory platform Mersana to receive $30 million upfront payment, up to $800 million in development, regulatory and commercial milestones, and tiered royalties up to the low

RHEA-AI

positive

12/14/22 8:00 AM

Nasdaq : MRSN

European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

RHEA-AI

very positive

12/02/22 4:05 PM

Nasdaq : MRSN

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

RHEA-AI

very positive

11/08/22 8:00 AM

Nasdaq : MRSN

conferences

Mersana Therapeutics to Present at Jefferies London Healthcare Conference

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

RHEA-AI

neutral

11/07/22 7:00 AM

Nasdaq : MRSN

earnings

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

Completed enrollment in UPLIFT clinical trial; topline data expected mid-2023; potential Biologics License Application (BLA) submission anticipated by the end of 2023 Initiated patient enrollment and dosing in Phase 1 clinical trial of XMT-1660 Strengthened balance sheet with $100 million upfront

RHEA-AI

very positive

11/04/22 4:05 PM

Nasdaq : MRSN

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

MRSN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.mersana.com
CeoAnna Protopapas
Security nameMersana Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees110
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address840 Memorial Dr
StateMassachusetts
CityCambridge
Zip02139-3789
CountryUS
Phone16174980020

About Mersana Therapeutics Inc

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana's second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana's customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company's early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company's Immunosynthen platform. In addition, multiple partners are using Mersana's Dolaflexin platform to advance their ADC pipelines.